Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Organogenesis Inc.
Takeda’s collaboration with the private UK biotech includes NASH and other liver disorders. Reliance will take on Amazon in the India pharmacy space with acquisition of Netmeds.
Surprise provision directs favorable Medicare Part B reimbursement for a handful of therapeutics beginning later this year.
Device and diagnostics fundraising slumped in Q2, but there was a substantial uptick in M&A activity. Device financings totaled just slightly over half of the previous quarter, while acquisitions grew almost six-fold, thanks primarily to Becton Dickinson's $23.5 billion play for CR Bard. Financing in diagnostics slid to $1.03 billion, less than half of Q1, whereas the $1.7 billion in M&As (most of that from PerkinElmer's $1.3 billion buy of EuroImmun) was more than double Q1's aggregate.
M&A deal activity waned in March, with a total of 9 deals completed in the month, down from 12 in February and 17 in March 2016. This third month brought the total number of deals for Q1 2017 to 33, a significant year-on-year decline compared to 51 in the first quarter of 2016.
- Other Names / Subsidiaries
- Avista Capital Partners
- Avista Healthcare Public Acquisition Corporation
- GCM Holding Corporation
- Inform Diagnostics, Inc.
- Kramer Laboratories
- Miraca Life Sciences, Inc.
- NuTech Medical
- NuTech Spine.